Latest Benign Prostatic Hyperplasia (BPH) News
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
Patients' pre-existing urinary problems influenced their perceptions of symptom relief after prostate cancer treatment.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Study documents significant improvements in frequency, urgency, and nocturia.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
Significant improvements in lower urinary tract symptoms are durable to 24 months, data show.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
New data show that the minimally invasive procedure is superior overall to TURP for treating BPH-related lower urinary tract symptoms.
Procedure partially blocks blood flow to the gland and appears to ease the need to urinate.
Three quarters of patients experienced significant improvements in lower urinary tract symptoms and quality of life observed and were satisfied with treatment.
Prostatic arterial embolization significantly reduced volumes of median lobes, central zones, peripheral zones, and whole prostate glands.
Men receiving common medical treatments for LUTS/BPH, including phytotherapy, experienced similar symptom relief.
The risk is 67% higher in men with a prostate size of 40.1-80 mL than those with smaller glands.
The risk of bladder outlet obstruction increased 34% per unit increase in serum PSA and decreased 23% per unit increase in maximal flow rate.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)